Tandem Diabetes Care (TNDM) and Vapotherm (VAPO) Critical Contrast

Tandem Diabetes Care (NASDAQ:TNDM) and Vapotherm (NYSE:VAPO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Earnings and Valuation

This table compares Tandem Diabetes Care and Vapotherm’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tandem Diabetes Care $107.60 million 22.66 -$73.03 million ($12.87) -3.30
Vapotherm N/A N/A N/A N/A N/A

Vapotherm has lower revenue, but higher earnings than Tandem Diabetes Care.

Profitability

This table compares Tandem Diabetes Care and Vapotherm’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tandem Diabetes Care -93.07% -204.32% -43.75%
Vapotherm N/A N/A N/A

Insider & Institutional Ownership

71.6% of Tandem Diabetes Care shares are held by institutional investors. 9.3% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Tandem Diabetes Care and Vapotherm, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tandem Diabetes Care 0 3 9 0 2.75
Vapotherm 0 0 4 0 3.00

Tandem Diabetes Care currently has a consensus price target of $44.38, indicating a potential upside of 4.41%. Vapotherm has a consensus price target of $25.50, indicating a potential upside of 48.69%. Given Vapotherm’s stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than Tandem Diabetes Care.

Summary

Vapotherm beats Tandem Diabetes Care on 5 of the 9 factors compared between the two stocks.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

About Vapotherm

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit and Q50 compressor; and disposable products comprising single-use disposables and nasal interfaces. The company sells its products to hospitals through a direct sales force in the United States; and through distributors in various countries internationally. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply